Verve Therapeutics, Inc.
Clinical trials sponsored by Verve Therapeutics, Inc., explained in plain language.
-
Gene-Editing shot aims to slash cholesterol that drugs Can't touch
Disease control Recruiting nowThis early-stage study tests a single dose of VERVE-201, a gene-editing therapy, in 36 adults with dangerously high cholesterol and triglycerides that don't respond to standard treatments. The treatment aims to permanently turn off a liver gene (ANGPTL3) to lower blood fats. The …
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Gene-Editing shot could slash cholesterol for good
Disease control Recruiting nowThis early-stage trial tests a single IV dose of VERVE-102, a gene-editing drug designed to permanently lower LDL (bad) cholesterol by turning off a specific gene in the liver. It involves 85 adults with inherited high cholesterol or early heart disease who still need lower chole…
Phase: PHASE1 • Sponsor: Verve Therapeutics, Inc. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC